Dermal Cell News Volume 5.27 | Aug 12 2019

TOP STORY

Tracing the Cellular Dynamics of Sebaceous Gland Development in Normal and Perturbed States

The authors applied large-scale quantitative fate mapping to define the patterns of cell fate behavior during sebaceous gland (SG) development and maintenance. They showed that the SG developed from a defined number of lineage-restricted progenitors that underwent a program of independent and stochastic cell fate decisions. [Nat Cell Biol] Abstract

(Ranked by impact factor of the journal)

DERMAL STEM CELLS & TISSUE REGENERATION

A ROCK Inhibitor Promotes Keratinocyte Survival and Paracrine Secretion, Enhancing Establishment of Primary Human Melanocytes and Melanocyte‐Keratinocyte Co‐Cultures

Researchers found that Y‐27632 promoted keratinocyte attachment and survival in a melanocyte culture system, resulting in not only better recovery, but also increased proliferation of melanocytes by a paracrine signaling pathway. [Pigment Cell Melanoma] Abstract

Keratinocytes Maintain Compartmentalization between Dermal Papilla and Fibroblasts in 3D Heterotypic Tri‐Cultures

Scientists reproduced hair follicle‐like constructs resembling the spatial orientation of different cells in vivo, to study the role of keratinocytes in maintaining cellular compartmentalization among hair follicle‐related cells. [Cell Prolif] Full Article

Implementation of an In Vitro Methodology for Phototoxicity Evaluation in a Human Keratinocyte Cell Line

The authors describe the implementation and validation of an in vitro methodology for phototoxicity evaluation based on the 3T3 neutral red uptake phototoxicity test using the HaCaT human keratinocyte cell line, and UVA/UVB radiation. [Toxicol In Vitro] Abstract

SKIN CANCERS & DISORDERS

A Fatty Acid Oxidation-Dependent Metabolic Shift Regulates the Adaptation of BRAF-Mutated Melanoma to MAPK Inhibitors

Melanoma cells treated with mitogen-activated protein kinase inhibitors displayed increased levels of CD36 and of peroxisome proliferator-activated receptor α-mediated and carnitine palmitoyltransferase 1A-dependent fatty acid oxidation. [Clin Cancer Res] Abstract

HO‐1 Downregulation Favors BRAF^V600 Melanoma Cell Death Induced by Vemurafenib/PLX4032 and Increases NK Recognition

Scientists investigated the role of heme oxygenase 1 (HO‐1) expression in Vemurafenib‐treated BRAFV600 melanoma cells in modulating their susceptibility to NK cell‐mediated recognition. [Int J Cancer] Abstract

C-Jun Drives Melanoma Progression in PTEN Wild Type Melanoma Cells

Investigators mapped the genome-wide occupancy of the AP-1 family member c-Jun in different melanoma cells and correlated AP-1 binding with transcriptome data to detect genes in melanoma regulated by c-Jun. [Cell Death Dis] Full Article

miR‐140‐5p Is Negatively Correlated with Proliferation, Invasion, and Tumorigenesis in Malignant Melanoma by Targeting SOX4 via the Wnt/β‐Catenin and NF‐κB Cascades

miR‐140‐5p directly targeted SOX4 and inhibited its expression in melanoma cells. miR‐140‐5p overexpression repressed melanoma cell proliferation and invasion and its effects were partially restored SOX4 overexpression. [J Cell Physiol] Abstract

Whole Transcriptome Analysis Reveals Correlation of Long Noncoding RNA ZEB1-AS1 with Invasive Profile in Melanoma

Researchers explored RNA-Seq data to search for long noncoding RNAs (lncRNAs) associated with melanoma progression. They found distinct lncRNA gene expression patterns across melanocytes, primary and metastatic melanoma cells. [Sci Rep] Full Article

Subscribe to one of our other 19 science newsletters such as Extracellular Matrix News & Cancer Stem Cell News.

Natural Melanoma-Derived Extracellular Vesicles

Melanoma cells produce a variety of extracellular vesicle (EV) types including shedding vesicles and exosomes (EXOs). These EVs are defined by their mechanism of cellular production. To date, the majority of EV investigations has centered around melanoma EXOs or small EVs. [Semin Cancer Biol] Abstract

Visit our reviews page to see a complete list of reviews in the dermal cell research field.

AB Science Reports the Analysis for Its Phase III Trial Evaluating Masitinib in Patients with Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma

AB Science SA reported the analysis for its Phase III trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta-membrane domain of c-Kit. [AB Science SA] Press Release

Provention Bio Initiates Phase Ib/IIa PREVAIL Clinical Trial Evaluating PRV-3279 in Lupus

Provention Bio, Inc. announced that it has dosed the first patients in its PREVAIL (PRV-3279 EVAluation In Lupus) study, a Phase Ib/IIa clinical trial evaluating PRV-3279. [Provention Bio, Inc.] Press Release

Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase Ib Trial

Evelo Biosciences, Inc. announced positive interim clinical data from the first cohort of patients with mild to moderate psoriasis from its ongoing Phase Ib trial of EDP1815, its clinical candidate for the treatment of inflammatory diseases. [Evelo Biosciences, Inc.] Press Release

Foamix Submits New Drug Application to US FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea

Foamix Pharmaceuticals Ltd. announced that it has submitted a New Drug Application to the FDA seeking approval for FMX103 for the treatment of moderate-to-severe papulopustular rosacea in patients 18 years of age and older. [Foamix Pharmaceuticals Ltd.] Press Release

Lenus Therapeutics Announces the Result of Complete Wound Healing on the Index Lesion of the First Subject in an Ongoing Single-Masked Phase II Trial with RGN-137 Dermal Gel for Epidermolysis Bullosa

Lenus Therapeutics, LLC announced that it has confirmed complete wound healing of the index lesion of the first subject enrolled in its ongoing single-masked Phase II clinical trial with RGN-137 dermal gel for epidermolysis bullosa. [Lenus Therapeutics, LLC (PR Newswire Association LLC.)] Press Release

Nektar Therapeutics and Bristol-Myers Squibb Announce US FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo^® (Nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma

Nektar Therapeutics and Bristol-Myers Squibb announced that the FDA has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin in combination with Bristol-Myers Squibb’s Opdivo^® for the treatment of patients with previously untreated unresectable or metastatic melanoma. [Nektar Therapeutics] Press Release

LEO Pharma Inc. Announces US Food and Drug Administration (FDA) Expanded Regulatory Approvals for Enstilar^® Foam and Taclonex^® Topical Suspension in Treatment of Plaque Psoriasis

LEO Pharma Inc. announced the FDA has expanded the approved indication for Enstilar^® Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older. [LEO Pharma Inc. (PR Newswire Association LLC.)] Press Release

Academia to FBI on Monitoring Chinese Scientists: “Tread Carefully”

Nearly two dozen higher education groups warn the government to be cautious when advising US research universities to keep an eye on students and faculty with ties to certain Chinese institutions. [The Scientist] Editorial

UK Announces Fast-Track Visa to Recruit Top Scientists

British Prime Minister Boris Johnson has announced a new fast-track visa to attract elite scientists to live and work in the UK, in light of the nation leaving the European Union later this year. “I want the UK to continue to be a global science superpower, and when we leave the EU we will support science and research and ensure that, far from losing out, the scientific community has a huge opportunity to develop and export our innovation around the world,” Johnson said in a statement. [The Scientist] Editorial

UC Faculty Protest Elsevier by Suspending Work for Cell Press

Faculty members at a number University of California (UC) schools have stopped serving on the editorial boards of journals published by Cell Press in protest of its parent company, Elsevier, not having reached a deal with UC for access to its publications. The 31 signatories of a letter to Elsevier, posted August 7^th online, write that unless Elsevier and UC can agree upon a new contract, they will not serve on the boards of Cell, Neuron, Immunity, Current Biology, and others. [The Scientist] Editorial

NEW Cancer Evolution and Combinatorial Cancer Therapies: Concepts and Challenges
January 19-23, 2020
Keystone, Colorado, United States

Visit our events page to see a complete list of events in the community.

NEW Student Biology – Cell Biology, Wound Healing, Gravitational Biology (German Aerospace Center)

Scientific Communications Coordinator (STEMCELL Technologies Inc.)

Postdoctoral Fellowship – Gene Therapy of the Human Skin (The University of British Columbia)

Research Fellow – Dermatology (University College London)

Postdoctoral Position – Immune Mechanisms of Allergic Diseases (Boston Children’s Hospital)

Faculty Position – Melanoma and Skin Immunobiology (Medical College of Wisconsin)

Doctoral Candidate – Tattoo Inks (Federal Institute for Risk Assessment)

Research Fellowship – Cancer Biology (Ninewells Hospital and Medical School)

Postdoctoral Fellowship – Cancer Immunology and Immunotherapy (H. Lee Moffitt Cancer Center)

Postdoctoral Fellow – Cancer Drug Response Research (University of Texas at Austin)

Research Lab Specialist – Tumor Microenvironment & Cell Behavior (University of Southern California)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Dermal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.